PHILADELPHIA--(BUSINESS WIRE)--VintaBio, a biotech manufacturing technology company specializing in high-yield, high-purity viral vector production for reliable gene therapy access, will present ...
Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, and ...
The MarketWatch News Department was not involved in the creation of this content. HOUSTON, Sept. 8, 2025 /PRNewswire/ -- AAVivo, Inc., a pioneering biotechnology developing novel, precision targeted ...
Adeno-associated virus (AAV) gene therapy holds considerable promise for treating diseases caused by genetic defects or deficiencies, but the packaging capacity of AAV vectors limits the potential ...
Circio Holding announces, it is presenting new and confirmatory in vivo data for its circVec-AAV expression platform. The in vivo results show, for the first time, up to 50-fold enhanced AAV-circVec ...
Next step in a broader collaboration to support VVMF build viral vector manufacturing capabilities Oxford, UK – 18 March 2026: OXB (LSE: OXB), a ...
Although the targets of biomanufacturing have evolved from therapeutic proteins to “advanced therapies” and now to gene therapies, the issues and solutions remain the same. The production of safe, ...
HOUSTON, Sept. 8, 2025 /PRNewswire/ -- AAVivo, Inc., a pioneering biotechnology developing novel, precision targeted biotherapeutics to enable in vivo generation of CAR-T cells, today announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results